Adjuvia Therapeutics Closes $8 Million Series Seed Financing to Advance Novel Mitochondrial Disease Therapy into the ...
Funding will support IND submission for lead candidate ATI-105 and initiation of Phase 1 clinical trials in Fall 2026 SAN FRANCISCO--(BUSINESS WIRE)--#AdjuviaTherapeutics--Adjuvia Therapeutics, a biotechnology company developing therapeutics to treat …